[et_pb_section fb_built=\u00bb1″ custom_padding_last_edited=\u00bbon|desktop\u00bb admin_label=\u00bbHeader\u00bb _builder_version=\u00bb4.17.4″ background_enable_image=\u00bboff\u00bb background_size=\u00bbcontain\u00bb background_position=\u00bbtop_right\u00bb custom_padding=\u00bb11px||31px||false|false\u00bb custom_padding_tablet=\u00bb2px|0px|50px|0px|false|false\u00bb custom_padding_phone=\u00bb3px|0px|50px|0px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row _builder_version=\u00bb4.16″ max_width=\u00bb1280px\u00bb custom_margin=\u00bb-11px|auto||auto||\u00bb custom_padding=\u00bb8px||2px|||\u00bb use_custom_width=\u00bbon\u00bb custom_width_px=\u00bb1280px\u00bb collapsed=\u00bbon\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.16″ custom_padding=\u00bb|||\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover=\u00bb|||\u00bb][et_pb_text _builder_version=\u00bb4.20.1″ _module_preset=\u00bbdefault\u00bb text_font=\u00bb|700|||||||\u00bb text_font_size=\u00bb16px\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n
Acceso abierto<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=\u00bb4.16.0″ _dynamic_attributes=\u00bbcontent\u00bb text_font=\u00bbEB Garamond||||||||\u00bb text_text_color=\u00bb#000000″ text_font_size=\u00bb50px\u00bb text_line_height=\u00bb1.3em\u00bb header_font=\u00bbEB Garamond||||||||\u00bb header_font_size=\u00bb54px\u00bb header_line_height=\u00bb1.3em\u00bb header_4_font=\u00bb|700||on|||||\u00bb header_4_font_size=\u00bb16px\u00bb header_4_letter_spacing=\u00bb2px\u00bb header_4_line_height=\u00bb2em\u00bb max_width=\u00bb900px\u00bb text_font_size_tablet=\u00bb\u00bb text_font_size_phone=\u00bb15px\u00bb text_font_size_last_edited=\u00bbon|tablet\u00bb text_line_height_tablet=\u00bb\u00bb text_line_height_phone=\u00bb1.6em\u00bb text_line_height_last_edited=\u00bbon|phone\u00bb header_font_size_tablet=\u00bb50px\u00bb header_font_size_phone=\u00bb32px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF90aXRsZSIsInNldHRpbmdzIjp7ImJlZm9yZSI6IiIsImFmdGVyIjoiIn19@[\/et_pb_text][et_pb_blurb title=\u00bbAgust\u00edn Llanos, (1) Mat\u00edas Guaraglia, (1)\u00bb use_icon=\u00bbon\u00bb font_icon=\u00bb||divi||400″ icon_color=\u00bb#3cbebe\u00bb icon_placement=\u00bbleft\u00bb content_max_width=\u00bb1100px\u00bb image_icon_width_last_edited=\u00bboff|desktop\u00bb _builder_version=\u00bb4.27.4″ header_font=\u00bb|600|||||||\u00bb header_font_size=\u00bb18px\u00bb header_line_height=\u00bb1.6em\u00bb body_font=\u00bb||||||||\u00bb body_font_size=\u00bb13px\u00bb body_line_height=\u00bb2em\u00bb header_font_size_tablet=\u00bb\u00bb header_font_size_phone=\u00bb15px\u00bb header_font_size_last_edited=\u00bbon|phone\u00bb body_line_height_tablet=\u00bb\u00bb body_line_height_phone=\u00bb1.6em\u00bb body_line_height_last_edited=\u00bbon|phone\u00bb image_max_width_phone=\u00bb50px\u00bb image_max_width_last_edited=\u00bboff|desktop\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n
(1)<\/sup> Residente del Servicio de Cardiolog\u00eda [\/et_pb_blurb][et_pb_text _builder_version=\u00bb4.27.4″ text_font=\u00bb||||||||\u00bb text_font_size=\u00bb12px\u00bb text_line_height=\u00bb1.6em\u00bb header_font=\u00bb||||||||\u00bb header_2_font=\u00bb||||||||\u00bb header_3_font=\u00bbEB Garamond||||||||\u00bb header_3_font_size=\u00bb24px\u00bb header_3_line_height=\u00bb1.4em\u00bb header_4_font=\u00bb|700||on|||||\u00bb header_4_text_color=\u00bb#ffdaa4″ header_4_font_size=\u00bb12px\u00bb header_4_letter_spacing=\u00bb2px\u00bb header_4_line_height=\u00bb2em\u00bb hover_enabled=\u00bb0″ text_line_height_tablet=\u00bb\u00bb text_line_height_phone=\u00bb1.6em\u00bb text_line_height_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0″]<\/p>\n Citaci\u00f3n sugerida:<\/strong> Llanos A y col. Amiloidosis card\u00edaca: Caracter\u00edsticas basales, diagn\u00f3stico y pron\u00f3stico de una cohorte unic\u00e9ntrica. Anuario (Fund. Dr. J. R. Villavicencio) 2025;32. Disponible en: https:\/\/villavicencio.org.ar\/anuario\/32-amiloidosis-cardiaca-caracteristicas<\/a><\/span>. ARK: https:\/\/id.caicyt.gov.ar\/ark:\/s2796762x\/bk9kgt6gi<\/span><\/a><\/p>\n Este es un art\u00edculo de acceso abierto distribuido bajo los t\u00e9rminos de Creative Commons Attribution License (https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/deed.es), esto permite que Ud. lo use, lo distribuya y lo adapte, sin prop\u00f3sitos comerciales, siempre que se cite correctamente el trabajo original. Si crea un nuevo material con \u00e9l, debe distribuirlo con la misma licencia.<\/p>\n [\/et_pb_text][et_pb_button button_url=\u00bb\/anuario\/32\/amiloidosis-cardiaca-caracteristicas.pdf\u00bb url_new_window=\u00bbon\u00bb button_text=\u00bbDescargar art\u00edculo\u00bb button_alignment=\u00bbright\u00bb _builder_version=\u00bb4.27.4″ custom_button=\u00bbon\u00bb button_text_size=\u00bb12px\u00bb button_text_color=\u00bb#3cbebe\u00bb button_bg_color=\u00bbrgba(60,190,190,0.1)\u00bb button_border_width=\u00bb10px\u00bb button_border_color=\u00bbrgba(0,0,0,0)\u00bb button_border_radius=\u00bb100px\u00bb button_letter_spacing=\u00bb1px\u00bb button_font=\u00bb|700||on|||||\u00bb custom_padding=\u00bb10px|20px|10px|20px|true|true\u00bb button_letter_spacing_hover=\u00bb1px\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb button_text_size__hover_enabled=\u00bboff\u00bb button_one_text_size__hover_enabled=\u00bboff\u00bb button_two_text_size__hover_enabled=\u00bboff\u00bb button_text_color__hover_enabled=\u00bboff\u00bb button_one_text_color__hover_enabled=\u00bboff\u00bb button_two_text_color__hover_enabled=\u00bboff\u00bb button_border_width__hover_enabled=\u00bboff\u00bb button_one_border_width__hover_enabled=\u00bboff\u00bb button_two_border_width__hover_enabled=\u00bboff\u00bb button_border_color__hover_enabled=\u00bboff\u00bb button_one_border_color__hover_enabled=\u00bboff\u00bb button_two_border_color__hover_enabled=\u00bboff\u00bb button_border_radius__hover_enabled=\u00bboff\u00bb button_one_border_radius__hover_enabled=\u00bboff\u00bb button_two_border_radius__hover_enabled=\u00bboff\u00bb button_letter_spacing__hover_enabled=\u00bbon\u00bb button_letter_spacing__hover=\u00bb1px\u00bb button_one_letter_spacing__hover_enabled=\u00bboff\u00bb button_two_letter_spacing__hover_enabled=\u00bboff\u00bb button_bg_color__hover_enabled=\u00bboff\u00bb button_one_bg_color__hover_enabled=\u00bboff\u00bb button_two_bg_color__hover_enabled=\u00bboff\u00bb][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1″ admin_label=\u00bbCourses\u00bb _builder_version=\u00bb4.16″ custom_padding=\u00bb1px|0px|62px|0px|false|false\u00bb locked=\u00bboff\u00bb collapsed=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row custom_padding_last_edited=\u00bbon|phone\u00bb _builder_version=\u00bb4.16″ background_color=\u00bb#ffffff\u00bb max_width=\u00bb1280px\u00bb custom_padding=\u00bb12px|40px|12px|40px|true|false\u00bb custom_padding_tablet=\u00bb\u00bb custom_padding_phone=\u00bb|20px||20px||true\u00bb animation_style=\u00bbzoom\u00bb animation_intensity_zoom=\u00bb2%\u00bb border_radii=\u00bbon|12px|12px|12px|12px\u00bb box_shadow_style=\u00bbpreset1″ box_shadow_vertical=\u00bb50px\u00bb box_shadow_blur=\u00bb80px\u00bb box_shadow_color=\u00bbrgba(15,19,25,0.1)\u00bb use_custom_width=\u00bbon\u00bb custom_width_px=\u00bb1280px\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.16″ custom_padding=\u00bb|||\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover=\u00bb|||\u00bb][et_pb_text _builder_version=\u00bb4.27.4″ text_font=\u00bb||||||||\u00bb text_font_size=\u00bb15px\u00bb text_line_height=\u00bb2em\u00bb header_font=\u00bb||||||||\u00bb header_2_font=\u00bb||||||||\u00bb header_3_font=\u00bbEB Garamond||||||||\u00bb header_3_font_size=\u00bb24px\u00bb header_3_line_height=\u00bb1.4em\u00bb header_4_font=\u00bb|700||on|||||\u00bb header_4_text_color=\u00bb#ffdaa4″ header_4_font_size=\u00bb12px\u00bb header_4_letter_spacing=\u00bb2px\u00bb header_4_line_height=\u00bb2em\u00bb text_line_height_tablet=\u00bb\u00bb text_line_height_phone=\u00bb1.6em\u00bb text_line_height_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n Introducci\u00f3n: La amiloidosis es una enfermedad caracterizada por el dep\u00f3sito de prote\u00ednas mal plegadas en diversos \u00f3rganos. Estas prote\u00ednas se acumulan en tejidos como el coraz\u00f3n, ri\u00f1ones y nervios, provocando s\u00edntomas variados y afecciones graves. La amiloidosis card\u00edaca puede causar miocardiopat\u00eda infiltrativa y se manifiesta com\u00fanmente como insuficiencia card\u00edaca. [\/et_pb_text][et_pb_text _builder_version=\u00bb4.27.4″ text_font=\u00bb||||||||\u00bb text_font_size=\u00bb15px\u00bb text_line_height=\u00bb2em\u00bb header_font=\u00bb||||||||\u00bb header_2_font=\u00bb||||||||\u00bb header_3_font=\u00bbEB Garamond||||||||\u00bb header_3_font_size=\u00bb24px\u00bb header_3_line_height=\u00bb1.4em\u00bb header_4_font=\u00bb|700||on|||||\u00bb header_4_text_color=\u00bb#ffdaa4″ header_4_font_size=\u00bb12px\u00bb header_4_letter_spacing=\u00bb2px\u00bb header_4_line_height=\u00bb2em\u00bb text_line_height_tablet=\u00bb\u00bb text_line_height_phone=\u00bb1.6em\u00bb text_line_height_last_edited=\u00bbon|phone\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n Amiloidosis, miocardiopat\u00eda, insuficiencia card\u00edaca, transtiretina, cadenas livianas, tafamidis<\/p>\n [\/et_pb_text][et_pb_text _builder_version=\u00bb4.27.4″ text_font=\u00bb||||||||\u00bb text_font_size=\u00bb15px\u00bb text_line_height=\u00bb2em\u00bb header_font=\u00bb||||||||\u00bb header_2_font=\u00bb||||||||\u00bb header_3_font=\u00bbEB Garamond||||||||\u00bb header_3_font_size=\u00bb24px\u00bb header_3_line_height=\u00bb1.4em\u00bb header_4_font=\u00bb|700||on|||||\u00bb header_4_text_color=\u00bb#ffdaa4″ header_4_font_size=\u00bb12px\u00bb header_4_letter_spacing=\u00bb2px\u00bb header_4_line_height=\u00bb2em\u00bb text_line_height_tablet=\u00bb\u00bb text_line_height_phone=\u00bb1.6em\u00bb text_line_height_last_edited=\u00bbon|phone\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n [\/et_pb_text][et_pb_text _builder_version=\u00bb4.27.4″ text_font=\u00bb||||||||\u00bb text_font_size=\u00bb15px\u00bb text_line_height=\u00bb2em\u00bb header_font=\u00bb||||||||\u00bb header_2_font=\u00bb||||||||\u00bb header_3_font=\u00bbEB Garamond||||||||\u00bb header_3_font_size=\u00bb24px\u00bb header_3_line_height=\u00bb1.4em\u00bb header_4_font=\u00bb|700||on|||||\u00bb header_4_text_color=\u00bb#ffdaa4″ header_4_font_size=\u00bb12px\u00bb header_4_letter_spacing=\u00bb2px\u00bb header_4_line_height=\u00bb2em\u00bb text_line_height_tablet=\u00bb\u00bb text_line_height_phone=\u00bb1.6em\u00bb text_line_height_last_edited=\u00bbon|phone\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n Introduction: Amyloidosis is a disease characterized by the deposition of misfolded proteins in various organs. These proteins accumulate in tissues such as the heart, kidneys and nerves, causing varied symptoms and severe conditions. Cardiac amyloidosis can lead to infiltrative cardiomyopathy and commonly manifests as heart failure.<\/p>\n Objective: To describe the characteristics of a cohort of patients diagnosed with cardiac amyloidosis and to evaluate their prognosis during follow-up.<\/p>\n Methods: A retrospective study was conducted in patients diagnosed with cardiac amyloidosis at the Instituto Cardiovascular de Rosario from November 1st, <\/sup>2017 to August 10th<\/sup>, 2024. Demographic data, history, time to diagnosis, diagnostic methods, type of amyloidosis, and clinical and laboratory variables were collected.<\/p>\n Results: Sixty four patients were diagnosed, with an increase in diagnoses in recent years. A total of 92.1% presented amyloidosis due to transthyretin (ATTR) and 7.9% due to light chains (AL). The mean age was 78.1 years and only 12.5 % were women. The median time from symptom onset to diagnosis was 6 months, with a notable decrease in recent years. The most commonly used diagnostic method was the single-photon emission computerized tomography (SPECT) with pyrophosphate in 92.1 % of cases. Only 25% of patients were treated with tafamidis. During follow-up, 26.5 % of the patients died and 37.5 % were hospitalized due to heart failure.<\/p>\n Conclusion: The diagnosis of amyloidosis has increased in the center studied, and the time from symptom onset to diagnosis has decreased. High morbidity and mortality were observed among patients.<\/p>\n [\/et_pb_text][et_pb_text _builder_version=\u00bb4.27.4″ text_font=\u00bb||||||||\u00bb text_font_size=\u00bb15px\u00bb text_line_height=\u00bb2em\u00bb header_font=\u00bb||||||||\u00bb header_2_font=\u00bb||||||||\u00bb header_3_font=\u00bbEB Garamond||||||||\u00bb header_3_font_size=\u00bb24px\u00bb header_3_line_height=\u00bb1.4em\u00bb header_4_font=\u00bb|700||on|||||\u00bb header_4_text_color=\u00bb#ffdaa4″ header_4_font_size=\u00bb12px\u00bb header_4_letter_spacing=\u00bb2px\u00bb header_4_line_height=\u00bb2em\u00bb text_line_height_tablet=\u00bb\u00bb text_line_height_phone=\u00bb1.6em\u00bb text_line_height_last_edited=\u00bbon|phone\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n Amyloidosis, cardiomyopathy, heart failure, transthyretin, light chain, tafamidis.<\/p>\n [\/et_pb_text][et_pb_text _builder_version=\u00bb4.27.4″ text_font=\u00bb||||||||\u00bb text_font_size=\u00bb15px\u00bb text_line_height=\u00bb2em\u00bb header_font=\u00bb||||||||\u00bb header_2_font=\u00bb||||||||\u00bb header_3_font=\u00bbEB Garamond||||||||\u00bb header_3_font_size=\u00bb24px\u00bb header_3_line_height=\u00bb1.4em\u00bb header_4_font=\u00bb|700||on|||||\u00bb header_4_text_color=\u00bb#ffdaa4″ header_4_font_size=\u00bb12px\u00bb header_4_letter_spacing=\u00bb2px\u00bb header_4_line_height=\u00bb2em\u00bb text_line_height_tablet=\u00bb\u00bb text_line_height_phone=\u00bb1.6em\u00bb text_line_height_last_edited=\u00bbon|phone\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n La amiloidosis es una patolog\u00eda causada por el dep\u00f3sito extracelular de prote\u00ednas mal plegadas en diversos \u00f3rganos.1,2<\/sup> Si bien existen muchos tipos diferentes de amiloidosis, en todos los casos las prote\u00ednas mal plegadas, llamadas amiloides (que significa \u00absemejante al almid\u00f3n\u00bb), adoptan una forma particular que hace que sea dif\u00edcil para el cuerpo degradarlas. Debido a este mal plegamiento, las prote\u00ednas amiloides se unen y forman fibras lineales r\u00edgidas (o fibrillas) que se acumulan en los \u00f3rganos y tejidos de nuestro cuerpo. Seg\u00fan d\u00f3nde se acumulen los amiloides, como en el ri\u00f1\u00f3n, el coraz\u00f3n y los nervios, pueden manifestarse distintos s\u00edntomas y afecciones potencialmente mortales. El dep\u00f3sito de amiloide en el coraz\u00f3n, causa una miocardiopat\u00eda infiltrativa\/restrictiva.3,4<\/sup> La afecci\u00f3n cardiaca es el factor predictor de peor pron\u00f3stico, y la forma de presentaci\u00f3n m\u00e1s frecuente es la insuficiencia cardiaca, aunque otras como las arritmias y los trastornos de conducci\u00f3n pueden preceder en a\u00f1os al diagn\u00f3stico de la enfermedad (Figura 1).5,6<\/sup><\/p>\n [\/et_pb_text][et_pb_text _builder_version=\u00bb4.27.4″ text_font=\u00bb||||||||\u00bb text_font_size=\u00bb15px\u00bb text_line_height=\u00bb2em\u00bb header_font=\u00bb||||||||\u00bb header_2_font=\u00bb||||||||\u00bb header_3_font=\u00bbEB Garamond||||||||\u00bb header_3_font_size=\u00bb24px\u00bb header_3_line_height=\u00bb1.4em\u00bb header_4_font=\u00bb|700||on|||||\u00bb header_4_text_color=\u00bb#ffdaa4″ header_4_font_size=\u00bb12px\u00bb header_4_letter_spacing=\u00bb2px\u00bb header_4_line_height=\u00bb2em\u00bb text_line_height_tablet=\u00bb\u00bb text_line_height_phone=\u00bb1.6em\u00bb text_line_height_last_edited=\u00bbon|phone\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n Describir las caracter\u00edsticas de una cohorte de pacientes diagnosticados de amiloidosis card\u00edaca y su pron\u00f3stico en el seguimiento.<\/p>\n [\/et_pb_text][et_pb_text _builder_version=\u00bb4.27.4″ text_font=\u00bb||||||||\u00bb text_font_size=\u00bb15px\u00bb text_line_height=\u00bb2em\u00bb header_font=\u00bb||||||||\u00bb header_2_font=\u00bb||||||||\u00bb header_3_font=\u00bbEB Garamond||||||||\u00bb header_3_font_size=\u00bb24px\u00bb header_3_line_height=\u00bb1.4em\u00bb header_4_font=\u00bb|700||on|||||\u00bb header_4_text_color=\u00bb#ffdaa4″ header_4_font_size=\u00bb12px\u00bb header_4_letter_spacing=\u00bb2px\u00bb header_4_line_height=\u00bb2em\u00bb text_line_height_tablet=\u00bb\u00bb text_line_height_phone=\u00bb1.6em\u00bb text_line_height_last_edited=\u00bbon|phone\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n Se evalu\u00f3 una cohorte retrospectiva de pacientes consecutivos diagnosticados de amiloidosis card\u00edaca en nuestro centro, Instituto Cardiovascular de Rosario, desde el 01\/11\/2017 hasta el 10\/08\/2024. Para el an\u00e1lisis se obtuvo la informaci\u00f3n de historia cl\u00ednica informatizada de la Unidad de Insuficiencia Card\u00edaca. Se recolectaron variables demogr\u00e1ficas, antecedentes cardiovasculares, tiempo al diagn\u00f3stico desde el inicio de los s\u00edntomas, m\u00e9todo diagn\u00f3stico, tipo de amiloidosis, variables cl\u00ednicas, de laboratorio, electrocardiogr\u00e1ficas, ecocardiogr\u00e1ficas y de seguimiento.\u00a0<\/p>\n [\/et_pb_text][et_pb_text _builder_version=\u00bb4.27.4″ text_font=\u00bb||||||||\u00bb text_font_size=\u00bb15px\u00bb text_line_height=\u00bb2em\u00bb header_font=\u00bb||||||||\u00bb header_2_font=\u00bb||||||||\u00bb header_3_font=\u00bbEB Garamond||||||||\u00bb header_3_font_size=\u00bb24px\u00bb header_3_line_height=\u00bb1.4em\u00bb header_4_font=\u00bb|700||on|||||\u00bb header_4_text_color=\u00bb#ffdaa4″ header_4_font_size=\u00bb12px\u00bb header_4_letter_spacing=\u00bb2px\u00bb header_4_line_height=\u00bb2em\u00bb text_line_height_tablet=\u00bb\u00bb text_line_height_phone=\u00bb1.6em\u00bb text_line_height_last_edited=\u00bbon|phone\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n De los pacientes derivados por sospecha diagn\u00f3stica de amiloidosis, se realiz\u00f3 el diagn\u00f3stico en 64 pacientes\u00a0(Tabla 1). <\/sup>El diagn\u00f3stico se increment\u00f3 en los \u00faltimos a\u00f1os. Cincuenta y nueve (92,1\u00a0%) tuvieron diagn\u00f3stico de amiloidosis por transtiretina (ATTR)\u00a0y cinco pacientes (7,9\u00a0%) por cadenas livianas (AL) (Figura 2). La media de edad de los pacientes fue de 78,1 a\u00f1os; solo 8 (12,5 016\u00a0%) eran mujeres, con una media de \u00edndice de masa corporal de 27,4. Como dato importante se observ\u00f3 que la mediana de tiempo desde el inicio de los s\u00edntomas al diagn\u00f3stico fue de 6 meses [1-18], con una clara diferencia en los \u00faltimos a\u00f1os, ya que (desde 2017-2021 la mediana fue de 14 meses [3,5-34,5] mientras que desde 2021-2024 la mediana fue de 2 meses [1-8]; p = 0,0171) (Figura 3). Dentro de los m\u00e9todos diagn\u00f3sticos utilizados, en 59 pacientes (92,1\u00a0%) fue con estudio de perfusi\u00f3n tomogr\u00e1fico (SPECT) con pirofosfato positivo y en 6 pacientes se requiri\u00f3 anatom\u00eda patol\u00f3gica, 2 biopsias de grasa abdominal y 4 biopsias endomioc\u00e1rdicas. Las comorbilidades m\u00e1s prevalentes fueron hipertensi\u00f3n arterial en 43 pacientes (67\u00a0%), tabaquismo o ex tabaquismo en 19 pacientes (29,6\u00a0%) y fibrilaci\u00f3n auricular permanente en 33 pacientes (51,5\u00a0%). Se observ\u00f3 que 20 pacientes (31,2\u00a0%) presentaban enfermedad del t\u00fanel carpiano y doce (18,7\u00a0%) alg\u00fan grado de neuropat\u00eda. S\u00f3lo 16 pacientes (25\u00a0%) recibieron tratamiento con tafamidis. [\/et_pb_text][et_pb_text _builder_version=\u00bb4.27.4″ text_font=\u00bb||||||||\u00bb text_font_size=\u00bb15px\u00bb text_line_height=\u00bb2em\u00bb header_font=\u00bb||||||||\u00bb header_2_font=\u00bb||||||||\u00bb header_3_font=\u00bbEB Garamond||||||||\u00bb header_3_font_size=\u00bb24px\u00bb header_3_line_height=\u00bb1.4em\u00bb header_4_font=\u00bb|700||on|||||\u00bb header_4_text_color=\u00bb#ffdaa4″ header_4_font_size=\u00bb12px\u00bb header_4_letter_spacing=\u00bb2px\u00bb header_4_line_height=\u00bb2em\u00bb text_line_height_tablet=\u00bb\u00bb text_line_height_phone=\u00bb1.6em\u00bb text_line_height_last_edited=\u00bbon|phone\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n El bajo porcentaje de pacientes tratados con tafamidis evidencia la dificultad de su accesibilidad en nuestro medio. A su vez, los pacientes diagnosticados presentaron una morbimortalidad elevada al seguimiento.7 <\/sup>El m\u00e9todo diagn\u00f3stico de elecci\u00f3n fue el SPECT con pirofosfato.8,9<\/sup><\/p>\n [\/et_pb_text][et_pb_text _builder_version=\u00bb4.27.4″ text_font=\u00bb||||||||\u00bb text_font_size=\u00bb15px\u00bb text_line_height=\u00bb2em\u00bb header_font=\u00bb||||||||\u00bb header_2_font=\u00bb||||||||\u00bb header_3_font=\u00bbEB Garamond||||||||\u00bb header_3_font_size=\u00bb24px\u00bb header_3_line_height=\u00bb1.4em\u00bb header_4_font=\u00bb|700||on|||||\u00bb header_4_text_color=\u00bb#ffdaa4″ header_4_font_size=\u00bb12px\u00bb header_4_letter_spacing=\u00bb2px\u00bb header_4_line_height=\u00bb2em\u00bb text_line_height_tablet=\u00bb\u00bb text_line_height_phone=\u00bb1.6em\u00bb text_line_height_last_edited=\u00bbon|phone\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n El diagn\u00f3stico de amiloidosis se increment\u00f3 en los \u00faltimos a\u00f1os en nuestro centro. Por su parte el tiempo de aparici\u00f3n de s\u00edntomas hasta diagnosticada la enfermedad ha disminuido.<\/p>\n [\/et_pb_text][et_pb_text _builder_version=\u00bb4.25.2″ text_font=\u00bb||||||||\u00bb text_font_size=\u00bb15px\u00bb text_line_height=\u00bb2em\u00bb header_font=\u00bb||||||||\u00bb header_2_font=\u00bb||||||||\u00bb header_3_font=\u00bbEB Garamond||||||||\u00bb header_3_font_size=\u00bb24px\u00bb header_3_line_height=\u00bb1.4em\u00bb header_4_font=\u00bb|700||on|||||\u00bb header_4_text_color=\u00bb#ffdaa4″ header_4_font_size=\u00bb12px\u00bb header_4_letter_spacing=\u00bb2px\u00bb header_4_line_height=\u00bb2em\u00bb text_line_height_tablet=\u00bb\u00bb text_line_height_phone=\u00bb1.6em\u00bb text_line_height_last_edited=\u00bbon|phone\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n Los autores declaran no tener conflicto de intereses.<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1″ admin_label=\u00bbTablas\u00bb _builder_version=\u00bb4.16″ custom_padding=\u00bb1px|0px|62px|0px|false|false\u00bb locked=\u00bboff\u00bb collapsed=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row custom_padding_last_edited=\u00bbon|phone\u00bb _builder_version=\u00bb4.27.3″ background_color=\u00bb#ffffff\u00bb max_width=\u00bb1280px\u00bb custom_padding=\u00bb12px|40px|12px|40px|true|false\u00bb custom_padding_tablet=\u00bb\u00bb custom_padding_phone=\u00bb|20px||20px||true\u00bb animation_style=\u00bbzoom\u00bb animation_intensity_zoom=\u00bb2%\u00bb border_radii=\u00bbon|12px|12px|12px|12px\u00bb box_shadow_style=\u00bbpreset1″ box_shadow_vertical=\u00bb50px\u00bb box_shadow_blur=\u00bb80px\u00bb box_shadow_color=\u00bbrgba(15,19,25,0.1)\u00bb use_custom_width=\u00bbon\u00bb custom_width_px=\u00bb1280px\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.16″ custom_padding=\u00bb|||\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover=\u00bb|||\u00bb][et_pb_text _builder_version=\u00bb4.27.4″ text_font=\u00bb||||||||\u00bb text_font_size=\u00bb15px\u00bb text_line_height=\u00bb2em\u00bb header_font=\u00bb||||||||\u00bb header_2_font=\u00bb||||||||\u00bb header_3_font=\u00bbEB Garamond||||||||\u00bb header_3_font_size=\u00bb24px\u00bb header_3_line_height=\u00bb1.4em\u00bb header_4_font=\u00bb|700||on|||||\u00bb header_4_text_color=\u00bb#ffdaa4″ header_4_font_size=\u00bb12px\u00bb header_4_letter_spacing=\u00bb2px\u00bb header_4_line_height=\u00bb2em\u00bb text_line_height_tablet=\u00bb\u00bb text_line_height_phone=\u00bb1.6em\u00bb text_line_height_last_edited=\u00bbon|phone\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n Tabla 1: Caracter\u00edsticas basales de la poblaci\u00f3n con amiloidosis \u00a0<\/strong><\/p>\n<\/td>\n \u00a0<\/strong><\/p>\n<\/td>\n<\/tr>\n Pacientes, n <\/strong><\/p>\n<\/td>\n 64<\/p>\n<\/td>\n<\/tr>\n Edad (media)<\/strong><\/p>\n<\/td>\n 78,1 a\u00f1os<\/p>\n<\/td>\n<\/tr>\n Sexo femenino, n (%)<\/strong><\/p>\n<\/td>\n 8 (12,5)<\/p>\n<\/td>\n<\/tr>\n Tiempo de s\u00edntomas al Dx, mediana (RI)<\/strong><\/p>\n<\/td>\n 6 meses (1-18)<\/p>\n<\/td>\n<\/tr>\n SPECT (pirofosfato positivo), n (%)<\/strong><\/p>\n<\/td>\n 59 (92,1)<\/p>\n<\/td>\n<\/tr>\n Hipertensi\u00f3n arterial, n (%)<\/strong><\/p>\n<\/td>\n 43 (67)<\/p>\n<\/td>\n<\/tr>\n Tabaquismo o ex tabaquismo, n (%)<\/strong><\/p>\n<\/td>\n 19 (29,6)<\/p>\n<\/td>\n<\/tr>\n Fibrilaci\u00f3n auricular permanente, n (%)<\/strong><\/p>\n<\/td>\n 33 (51,5)<\/p>\n<\/td>\n<\/tr>\n Enfermedad del t\u00fanel carpiano, n (%)<\/strong><\/p>\n<\/td>\n 20 (21,2)<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Dx: diagn\u00f3stico, RI: rango intercuartilo, SPECT: estudio de perfusi\u00f3n tomogr\u00e1fico<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1″ admin_label=\u00bbTablas\u00bb _builder_version=\u00bb4.16″ custom_padding=\u00bb1px|0px|62px|0px|false|false\u00bb locked=\u00bboff\u00bb collapsed=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row custom_padding_last_edited=\u00bbon|phone\u00bb _builder_version=\u00bb4.16″ background_color=\u00bb#ffffff\u00bb max_width=\u00bb1280px\u00bb custom_padding=\u00bb12px|40px|12px|40px|true|false\u00bb custom_padding_tablet=\u00bb\u00bb custom_padding_phone=\u00bb|20px||20px||true\u00bb animation_style=\u00bbzoom\u00bb animation_intensity_zoom=\u00bb2%\u00bb border_radii=\u00bbon|12px|12px|12px|12px\u00bb box_shadow_style=\u00bbpreset1″ box_shadow_vertical=\u00bb50px\u00bb box_shadow_blur=\u00bb80px\u00bb box_shadow_color=\u00bbrgba(15,19,25,0.1)\u00bb use_custom_width=\u00bbon\u00bb custom_width_px=\u00bb1280px\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.16″ custom_padding=\u00bb|||\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover=\u00bb|||\u00bb][et_pb_text _builder_version=\u00bb4.27.4″ text_font=\u00bb||||||||\u00bb text_font_size=\u00bb15px\u00bb text_line_height=\u00bb2em\u00bb header_font=\u00bb||||||||\u00bb header_2_font=\u00bb||||||||\u00bb header_3_font=\u00bbEB Garamond||||||||\u00bb header_3_font_size=\u00bb24px\u00bb header_3_line_height=\u00bb1.4em\u00bb header_4_font=\u00bb|700||on|||||\u00bb header_4_text_color=\u00bb#ffdaa4″ header_4_font_size=\u00bb12px\u00bb header_4_letter_spacing=\u00bb2px\u00bb header_4_line_height=\u00bb2em\u00bb text_line_height_tablet=\u00bb\u00bb text_line_height_phone=\u00bb1.6em\u00bb text_line_height_last_edited=\u00bbon|phone\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n Figura 1: Fibrillas amiloides<\/strong><\/p>\n [\/et_pb_text][et_pb_image src=\u00bbhttps:\/\/villavicencio.org.ar\/anuario\/wp-content\/uploads\/2025\/05\/Amiloidosis1.jpg\u00bb title_text=\u00bbAmiloidosis\u00bb align=\u00bbcenter\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1″ admin_label=\u00bbTablas\u00bb _builder_version=\u00bb4.16″ custom_padding=\u00bb1px|0px|62px|0px|false|false\u00bb locked=\u00bboff\u00bb collapsed=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row custom_padding_last_edited=\u00bbon|phone\u00bb _builder_version=\u00bb4.16″ background_color=\u00bb#ffffff\u00bb max_width=\u00bb1280px\u00bb custom_padding=\u00bb12px|40px|12px|40px|true|false\u00bb custom_padding_tablet=\u00bb\u00bb custom_padding_phone=\u00bb|20px||20px||true\u00bb animation_style=\u00bbzoom\u00bb animation_intensity_zoom=\u00bb2%\u00bb border_radii=\u00bbon|12px|12px|12px|12px\u00bb box_shadow_style=\u00bbpreset1″ box_shadow_vertical=\u00bb50px\u00bb box_shadow_blur=\u00bb80px\u00bb box_shadow_color=\u00bbrgba(15,19,25,0.1)\u00bb use_custom_width=\u00bbon\u00bb custom_width_px=\u00bb1280px\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.16″ custom_padding=\u00bb|||\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover=\u00bb|||\u00bb][et_pb_text _builder_version=\u00bb4.27.4″ text_font=\u00bb||||||||\u00bb text_font_size=\u00bb15px\u00bb text_line_height=\u00bb2em\u00bb header_font=\u00bb||||||||\u00bb header_2_font=\u00bb||||||||\u00bb header_3_font=\u00bbEB Garamond||||||||\u00bb header_3_font_size=\u00bb24px\u00bb header_3_line_height=\u00bb1.4em\u00bb header_4_font=\u00bb|700||on|||||\u00bb header_4_text_color=\u00bb#ffdaa4″ header_4_font_size=\u00bb12px\u00bb header_4_letter_spacing=\u00bb2px\u00bb header_4_line_height=\u00bb2em\u00bb text_line_height_tablet=\u00bb\u00bb text_line_height_phone=\u00bb1.6em\u00bb text_line_height_last_edited=\u00bbon|phone\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n Figura 2: Tipo de amiloidosis<\/strong><\/p>\n [\/et_pb_text][et_pb_image src=\u00bbhttps:\/\/villavicencio.org.ar\/anuario\/wp-content\/uploads\/2025\/05\/Amiloidosis2.jpg\u00bb title_text=\u00bbAmiloidosis\u00bb align=\u00bbcenter\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][et_pb_text _builder_version=\u00bb4.27.4″ text_font=\u00bb||||||||\u00bb text_font_size=\u00bb15px\u00bb text_line_height=\u00bb2em\u00bb header_font=\u00bb||||||||\u00bb header_2_font=\u00bb||||||||\u00bb header_3_font=\u00bbEB Garamond||||||||\u00bb header_3_font_size=\u00bb24px\u00bb header_3_line_height=\u00bb1.4em\u00bb header_4_font=\u00bb|700||on|||||\u00bb header_4_text_color=\u00bb#ffdaa4″ header_4_font_size=\u00bb12px\u00bb header_4_letter_spacing=\u00bb2px\u00bb header_4_line_height=\u00bb2em\u00bb text_line_height_tablet=\u00bb\u00bb text_line_height_phone=\u00bb1.6em\u00bb text_line_height_last_edited=\u00bbon|phone\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n TTR: transtiretina, AL: Cadenas livianas<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1″ admin_label=\u00bbTablas\u00bb _builder_version=\u00bb4.16″ custom_padding=\u00bb1px|0px|62px|0px|false|false\u00bb locked=\u00bboff\u00bb collapsed=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row custom_padding_last_edited=\u00bbon|phone\u00bb _builder_version=\u00bb4.16″ background_color=\u00bb#ffffff\u00bb max_width=\u00bb1280px\u00bb custom_padding=\u00bb12px|40px|12px|40px|true|false\u00bb custom_padding_tablet=\u00bb\u00bb custom_padding_phone=\u00bb|20px||20px||true\u00bb animation_style=\u00bbzoom\u00bb animation_intensity_zoom=\u00bb2%\u00bb border_radii=\u00bbon|12px|12px|12px|12px\u00bb box_shadow_style=\u00bbpreset1″ box_shadow_vertical=\u00bb50px\u00bb box_shadow_blur=\u00bb80px\u00bb box_shadow_color=\u00bbrgba(15,19,25,0.1)\u00bb use_custom_width=\u00bbon\u00bb custom_width_px=\u00bb1280px\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.16″ custom_padding=\u00bb|||\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover=\u00bb|||\u00bb][et_pb_text _builder_version=\u00bb4.27.4″ text_font=\u00bb||||||||\u00bb text_font_size=\u00bb15px\u00bb text_line_height=\u00bb2em\u00bb header_font=\u00bb||||||||\u00bb header_2_font=\u00bb||||||||\u00bb header_3_font=\u00bbEB Garamond||||||||\u00bb header_3_font_size=\u00bb24px\u00bb header_3_line_height=\u00bb1.4em\u00bb header_4_font=\u00bb|700||on|||||\u00bb header_4_text_color=\u00bb#ffdaa4″ header_4_font_size=\u00bb12px\u00bb header_4_letter_spacing=\u00bb2px\u00bb header_4_line_height=\u00bb2em\u00bb text_line_height_tablet=\u00bb\u00bb text_line_height_phone=\u00bb1.6em\u00bb text_line_height_last_edited=\u00bbon|phone\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n Figura 3: Tiempo de s\u00edntomas al diagn\u00f3stico<\/strong><\/p>\n [\/et_pb_text][et_pb_image src=\u00bbhttps:\/\/villavicencio.org.ar\/anuario\/wp-content\/uploads\/2025\/05\/Amiloidosis3.jpg\u00bb title_text=\u00bbAmiloidosis\u00bb align=\u00bbcenter\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1″ admin_label=\u00bbCourses\u00bb _builder_version=\u00bb4.16″ custom_padding=\u00bb1px|0px|62px|0px|false|false\u00bb locked=\u00bboff\u00bb collapsed=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row custom_padding_last_edited=\u00bbon|phone\u00bb _builder_version=\u00bb4.16″ background_color=\u00bb#ffffff\u00bb max_width=\u00bb1280px\u00bb custom_padding=\u00bb12px|40px|12px|40px|true|false\u00bb custom_padding_tablet=\u00bb\u00bb custom_padding_phone=\u00bb|20px||20px||true\u00bb animation_style=\u00bbzoom\u00bb animation_intensity_zoom=\u00bb2%\u00bb border_radii=\u00bbon|12px|12px|12px|12px\u00bb box_shadow_style=\u00bbpreset1″ box_shadow_vertical=\u00bb50px\u00bb box_shadow_blur=\u00bb80px\u00bb box_shadow_color=\u00bbrgba(15,19,25,0.1)\u00bb use_custom_width=\u00bbon\u00bb custom_width_px=\u00bb1280px\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.16″ custom_padding=\u00bb|||\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover=\u00bb|||\u00bb][et_pb_text _builder_version=\u00bb4.27.4″ text_font=\u00bb||||||||\u00bb text_font_size=\u00bb12px\u00bb text_line_height=\u00bb2em\u00bb header_font=\u00bb||||||||\u00bb header_2_font=\u00bb||||||||\u00bb header_3_font=\u00bbEB Garamond||||||||\u00bb header_3_font_size=\u00bb24px\u00bb header_3_line_height=\u00bb1.4em\u00bb header_4_font=\u00bb|700||on|||||\u00bb header_4_text_color=\u00bb#ffdaa4″ header_4_font_size=\u00bb12px\u00bb header_4_letter_spacing=\u00bb2px\u00bb header_4_line_height=\u00bb2em\u00bb text_line_height_tablet=\u00bb\u00bb text_line_height_phone=\u00bb1.6em\u00bb text_line_height_last_edited=\u00bbon|phone\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n 1.\tBrice\u00f1o A, Dominguez F, Garcia Pav\u00eda P, y col. Amiloidosis. [citado 02\/10\/2024]. Disponible en: https:\/\/amiloidosis.es\/amiloidosis\/que-es-la-amiloidosis\/ La amiloidosis es una enfermedad caracterizada por el dep\u00f3sito de prote\u00ednas mal plegadas en diversos \u00f3rganos. Estas prote\u00ednas se acumulan en tejidos como el coraz\u00f3n, ri\u00f1ones y nervios, provocando s\u00edntomas variados y afecciones graves. La amiloidosis card\u00edaca puede causar miocardiopat\u00eda infiltrativa y se manifiesta com\u00fanmente como insuficiencia card\u00edaca.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[39,43],"tags":[38],"class_list":["post-1893","post","type-post","status-publish","format-standard","hentry","category-39","category-a32-articulos-originales","tag-anuario-32-2025"],"_links":{"self":[{"href":"https:\/\/villavicencio.org.ar\/anuario\/wp-json\/wp\/v2\/posts\/1893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/villavicencio.org.ar\/anuario\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/villavicencio.org.ar\/anuario\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/villavicencio.org.ar\/anuario\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/villavicencio.org.ar\/anuario\/wp-json\/wp\/v2\/comments?post=1893"}],"version-history":[{"count":6,"href":"https:\/\/villavicencio.org.ar\/anuario\/wp-json\/wp\/v2\/posts\/1893\/revisions"}],"predecessor-version":[{"id":1934,"href":"https:\/\/villavicencio.org.ar\/anuario\/wp-json\/wp\/v2\/posts\/1893\/revisions\/1934"}],"wp:attachment":[{"href":"https:\/\/villavicencio.org.ar\/anuario\/wp-json\/wp\/v2\/media?parent=1893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/villavicencio.org.ar\/anuario\/wp-json\/wp\/v2\/categories?post=1893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/villavicencio.org.ar\/anuario\/wp-json\/wp\/v2\/tags?post=1893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Instituto Cardiovascular de Rosario, Bv. Oro\u00f1o 450 (2000) Rosario, Argentina
Correspondencia a<\/strong>: agusllanos96@gmail.com
Fecha de publicaci\u00f3n<\/strong>: 19\/05\/2025<\/p>\nResumen<\/h3>\n
Objetivo: Describir las caracter\u00edsticas de una cohorte de pacientes diagnosticados con amiloidosis card\u00edaca y evaluar su pron\u00f3stico durante el seguimiento.
M\u00e9todos: Se realiz\u00f3 un estudio retrospectivo en pacientes diagnosticados de amiloidosis card\u00edaca en el Instituto Cardiovascular de Rosario entre el 01\/11\/2017 y el 10\/08\/2024. Se recopilaron datos demogr\u00e1ficos, antecedentes, tiempo hasta el diagn\u00f3stico, m\u00e9todos diagn\u00f3sticos, tipo de amiloidosis, y variables cl\u00ednicas y de laboratorio.
Resultados: Se diagnosticaron 64 pacientes, con un aumento en los diagn\u00f3sticos en los \u00faltimos a\u00f1os. El 92,1\u00a0% present\u00f3 amiloidosis por transtiretina (ATTR) y el 7,9\u00a0% por cadenas livianas (AL). La media de edad fue de 78,1 a\u00f1os y solo el 12,5\u00a0% eran mujeres. La mediana de tiempo desde el inicio de s\u00edntomas hasta el diagn\u00f3stico fue de 6 meses, con una notable disminuci\u00f3n en los \u00faltimos a\u00f1os. El m\u00e9todo diagn\u00f3stico m\u00e1s utilizado fue el estudio de perfusi\u00f3n tomogr\u00e1fico (SPECT) con pirofosfato en el 92,1\u00a0% de los casos. Solo el 25\u00a0% de los pacientes recibi\u00f3 tratamiento con tafamidis. Durante el seguimiento, el 26,5\u00a0% de los pacientes fallecieron y el 37,5\u00a0% se internaron por insuficiencia card\u00edaca.
Conclusi\u00f3n: El diagn\u00f3stico de amiloidosis ha aumentado en el centro estudiado, y el tiempo desde el inicio de s\u00edntomas hasta el diagn\u00f3stico ha disminuido. Se observ\u00f3 una alta morbimortalidad entre los pacientes.<\/p>\nPalabras clave<\/h3>\n
Cardiac Amyloidosis: Baseline Characteristics, Diagnosis, and Prognosis of a Single-Center Cohort..<\/h2>\n
Abstract<\/h3>\n
Keywords<\/h3>\n
Introducci\u00f3n<\/h3>\n
Objetivos<\/h3>\n
Material o poblaci\u00f3n y m\u00e9todos<\/h3>\n
Resultados<\/h3>\n
Durante el seguimiento fallecieron 17 pacientes (26,5\u00a0%), 24 (37,5\u00a0%) se internaron por insuficiencia card\u00edaca y la combinaci\u00f3n de internaci\u00f3n o muerte sucedi\u00f3 en 32 pacientes (50\u00a0%).<\/p>\nDiscusi\u00f3n<\/h3>\n
Conclusiones<\/h3>\n
Conflicto de intereses<\/h3>\n
<\/strong><\/strong><\/p>\n\n\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Bibliograf\u00eda<\/h3>\n
\n 2.\tMohty D, Damy T, Cosnay P, et al. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis. 2013;106:528-540. Disponible en: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S187521361300274X?via%3Dihub
\n 3.\tGonz\u00e1lez L\u00f3pez E, L\u00f3pez Sains \u00c1, Garcia Pavia P. Diagn\u00f3stico y tratamiento de la amiloidosis cardiaca por transtiretina. Progreso y esperanza. Revista espa\u00f1ola de cardiolog\u00eda. 2017;70:991-1004. Disponible en: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0300893217303500
\n 4.\tDonnelly JP, Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. Cleve Clin J Med. 2017;84:12-26. Disponible en: https:\/\/www.ccjm.org\/content\/84\/12_suppl_3\/12
\n 5.\tCarretero M, Aguirre M, Villanueva E y col. Caracter\u00edsticas y evoluci\u00f3n de los pacientes con amiloidosis sist\u00e9mica y compromiso card\u00edaco. Arch Cardiol M\u00e9x. 2021;92:60-67. Disponible en: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8771037\/
\n 6.\tRuberg FL, Grogan M, Hanna M, et al. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73:2872-2891. Disponible en: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0735109719347291
\n 7.\tPericet Rodr\u00edguez C, L\u00f3pez Aguilera J, Dur\u00e1n Torralba C, y col. Caracterizaci\u00f3n y pron\u00f3stico del paciente con amiloidosis cardiaca: experiencia de un centro. REC: CardioClinics. 2022;57:14-23. Disponible en: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S2605153221000388
\n 8.\tL\u00f3pez Sains A, Hernandez Hernandez A, Gonzalez Lopez E, y col. Perfil cl\u00ednico y evoluci\u00f3n de la amiloidosis cardiaca en un centro espa\u00f1ol de referencia. Revista espa\u00f1ola de cardiolog\u00eda. 2021;74:149-158. Disponible en: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0300893219306098
\n 9.\tOerlemans MIFJ, Rutten KHG, Minnema MC, et al. Cardiac amyloidosis: the need for early diagnosis. Neth Heart J. 2019;27:525-536. Disponible en: https:\/\/link.springer.com\/article\/10.1007\/s12471-019-1299-1[\/et_pb_text][et_pb_text _builder_version=\u00bb4.16″ text_font=\u00bb||||||||\u00bb text_font_size=\u00bb15px\u00bb text_line_height=\u00bb2em\u00bb header_font=\u00bb||||||||\u00bb header_2_font=\u00bb||||||||\u00bb header_3_font=\u00bbEB Garamond||||||||\u00bb header_3_font_size=\u00bb24px\u00bb header_3_line_height=\u00bb1.4em\u00bb header_4_font=\u00bb|700||on|||||\u00bb header_4_text_color=\u00bb#ffdaa4″ header_4_font_size=\u00bb12px\u00bb header_4_letter_spacing=\u00bb2px\u00bb header_4_line_height=\u00bb2em\u00bb text_line_height_tablet=\u00bb\u00bb text_line_height_phone=\u00bb1.6em\u00bb text_line_height_last_edited=\u00bbon|phone\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"